A5058703108- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Gut microbiota and health
- Immunotherapy and Immune Responses
- interferon and immune responses
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- RNA Research and Splicing
- Cancer Research and Treatments
- Melanoma and MAPK Pathways
- Pancreatic and Hepatic Oncology Research
- Atherosclerosis and Cardiovascular Diseases
- Mycobacterium research and diagnosis
- Immune cells in cancer
- Lung Cancer Research Studies
- Clostridium difficile and Clostridium perfringens research
- Epigenetics and DNA Methylation
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Adenosine and Purinergic Signaling
The University of Texas MD Anderson Cancer Center
2021-2025
University of Pittsburgh
2018-2021
Scripps MD Anderson Cancer Center
2021
Texas Christian University
2021
Background The degree of immune infiltration in tumors, especially CD8 + T cells, greatly impacts patient disease course and response to interventional immunotherapy. Enhancement tumor infiltrating lymphocyte (TIL) is a critical element efficacious therapy one that may be achieved via administration agents promote vascular normalization (VN) and/or induce the development tertiary lymphoid structures (TLS) within microenvironment (TME). Methods Low-dose stimulator interferon genes (STING)...
Background A first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2 + patients with advanced melanoma. Methods Patient monocyte-derived type-1-polarized dendritic cells were loaded HLA-A2-presented peptides derived from TBVA (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) injected intradermally as a vaccine into the upper...
The gut microbiome modulates the immune system and responses to immunotherapy in patients with late-stage melanoma. It is unknown whether fecal microbiota profiles differ between healthy individuals melanoma or if among different stages of Defining without those early-stage may reveal features associated disease progression.
Abstract Neoadjuvant treatment with immune checkpoint blockade (ICB) improves clinical benefit relative to adjuvant therapy in multiple types of cancer. Window opportunity studies employing neoadjuvant permit integrated assessments pathologic response along effects and mechanisms resistance the tumor microenvironment. Resistance including exclusion myeloid suppression have been shown be regulated by semaphorin 4D (SEMA4D) preclinical studies. A window study was designed evaluate activity...
Abstract Background: Immune checkpoint blockade (ICB) has revolutionized treatments for cancer; however, only a minority of patients achieve durable response. Landmark studies have now shown that B-cells and Tertiary Lymphoid Structures (TLS) within the tumor typify exceptional response to ICB. However, functional role TLS in cancer remains largely unexplored. Here, we produce evaluate therapeutic efficacy tumor-derived antibodies alone or combination with ICB-based regimen. Methods Results:...
Abstract Background: STS are poorly understood cancers for which systemic therapy options limited. Recent evidence suggests that some patients with two types of (undifferentiated pleomorphic sarcoma, UPS; dedifferentiated liposarcoma, DDLPS) benefit from ICB. Presence tertiary lymphoid structures (TLS) and B cells within the sarcoma tumor immune microenvironment (TME) is associated response to ICB longer survival. It remains unclear how populations this TME interact each other they evolve...
Abstract Purpose: Lynch syndrome (LS) is a hereditary condition with high lifetime risk of colorectal and endometrial cancers. Exercise non-pharmacologic intervention to reduce cancer risk, though its impact on patients LS has not been prospectively studied. Here, we evaluated the 12-month aerobic exercise cycling in biology immune system carriers. Patients Methods: To address this, enrolled 21 onto non-randomized, sequential assignation, clinical trial assess effect program that included...
<h3>Background</h3> The degree of immune infiltration in tumors, especially CD8+ T cells, greatly impacts patient disease course and response to interventional immunotherapy. Hence, enhancement TIL prevalence is a preferred clinical endpoint, one that may be achieved via administration agents normalize the tumor vasculature (VN) leading improved cell recruitment and/or induce development local tertiary lymphoid structures (TLS) within microenvironment (TME). <h3>Methods</h3> Low-dose STING...
9523 Background: Treatment with BRAF+/-MEK inhibition (BRAF+/-MEKi) has revolutionized treatment in melanoma and other cancers, but resistance is common innovative strategies are needed. Sexual dimorphism response to BRAF+/-MEKi have been noted, mechanisms behind this poorly understood hormonal modulation not well-studied setting. Methods: We examined outcomes by sex five clinical cohorts of patients (pts) (total n = 792, 362 female, 430 male) BRAF-mutated who were treated BRAF/MEKi either...